key: cord-0818498-fawxthy6
authors: Mrugala, Maciej M; Ostrom, Quinn T; Pressley, Shelley M; Taylor, Jennie; Thomas, Alissa A; Wefel, Jeffrey S; Coven, Scott L; Acquaye, Alvina A; Haynes, Chas; Agnihotri, Sameer; Lim, Michael; Peters, Katherine B; Sulman, Erik P; Salcido, Joanne T; Butowski, Nicholas A; Hervey-Jumper, Shawn; Mansouri, Alireza; Oliver, Kathy R; Porter, Alyx B; Nassiri, F; Schiff, D; Dunbar, Erin M; Hegi, Monika E; Armstrong, Terri S; van den Bent, Martin J; Chang, Susan M; Zadeh, Gelareh; Chheda, Milan G
title: The State of Neuro-Oncology During the COVID-19 Pandemic: A Worldwide Assessment
date: 2021-02-20
journal: Neurooncol Adv
DOI: 10.1093/noajnl/vdab035
sha: bae4073bcbde50722b87cdd33a9e5e1acc2c7a96
doc_id: 818498
cord_uid: fawxthy6

BACKGROUND: It remains unknown how the COVID-19 pandemic has changed neuro-oncology clinical practice, training and research efforts. Methods: We performed an international survey of practitioners, scientists, and trainees from 21 neuro-oncology organizations across 6 continents, April 24–May 17, 2020. We assessed clinical practice and research environments; institutional preparedness and support; and perceived impact on patients. RESULTS: Of 582 respondents, 258 (45%) were US-based, and 314 (55%) international. 94% participants reported changes in their clinical practice. 95% respondents converted at least some practice to telemedicine. 10% practitioners felt the need to see patients in person, specifically because of billing concerns and pressure from their institutions. 67% practitioners suspended enrollment for at least one clinical trial, including 62% suspending phase III trial enrollments. Over 50% believed neuro-oncology patients were at increased risk for COVID-19. 71% clinicians feared for their own personal safety or that of their families, specifically because of their clinical duties; 20% had inadequate PPE. While 69% reported increased stress, 44% received no psychosocial support from their institutions. 37% had salary reductions and 63% researchers temporarily closed their laboratories. However, the pandemic created positive changes in perceived patient satisfaction, communication quality, and technology use to deliver care and mediate interactions with other practitioners. CONCLUSIONS: The pandemic has changed treatment schedules and limited investigational treatment options. Institutional lack of support created clinician and researcher anxiety. Communication with patients was satisfactory. We make recommendations to guide clinical and scientific infrastructure moving forward, and address the personal challenges of providers and researchers.

The COVID-19 pandemic has created many challenges for healthcare 1 . Neuro-oncology, which focuses on treating patients with primary and metastatic brain and central nervous system (CNS) tumors and neurologic complications of cancer, has faced challenges, particularly in maintaining quality patient care and conducting clinical trials and laboratory research.

The provider pool in neuro-oncology is relatively small. In 2018, there were 2600 members in the Society for Neuro-Oncology (SNO) database, of which 1040 (40%) were clinical members, including physicians, nurses, and nurse practitioners. Equally small numbers of neuro-oncologists practice in Europe, Asia, and the rest of the developed world. In the US, approximately 25,000 malignant primary brain tumors are diagnosed annually 2 . There are significant differences in incidence by world region, with the highest incidence of malignant brain tumors in Northern Europe and Canada, and the lowest in Southeast Asia.

Gliomas are the most aggressive primary brain tumor, and they make up the majority of diagnoses in neuro-oncology. Standard treatment for high grade gliomas includes surgical resection; followed by radiation and temozolomide, an alkylating chemotherapy; and more recently, adjuvant use of tumor treating fields. Often during the course of care, patients receive dexamethasone, which reduces edema; bevacizumab, a monoclonal antibody that reduces angiogenesis and edema; and/or lomustine, an alkylating chemotherapy. Radiation, temozolomide, and lomustine all commonly cause myelosuppression and lymphopenia 3, 4 .

Immunotherapy is not approved for primary brain tumors; it remains under investigation and is sometimes used as an off-label treatment at the time of tumor recurrence.

The pandemic has required re-organization of clinic visits, treatment and diagnostic testing schedules, and development of new processes managing therapy-related complications 5 . Patient management guidelines [6] [7] [8] have emerged, and discussions have A c c e p t e d M a n u s c r i p t 7 centered on how to approach brain tumor patient treatment in resource-limited settings and when significant exposure risk to patients and health care providers exists 9 . These recommendations notwithstanding, it remains unknown as to what practically changed during the pandemic. The pandemic has also affected medical teams. While physicians and allied professionals are accustomed to dealing with stress and dying patients, the burden of these new challenges has been unprecedented on professional and personal lives. Clinicians need support during the COVID-19 pandemic 10 , and guidelines exist for managing psychological stress and maintaining healthy physical and mental states 11 . However, we lack basic measurements of what clinicians and researchers are experiencing.

Medical education was restructured so medical students, residents, and fellows may continue learning to take care of patients and advance through their training programs 12, 13 .

Many programs are facing financial challenges that jeopardize the continuity of their training mission and the ability to accept new trainees.

Lastly, scientists in neuro-oncology, attempting to understand the mechanisms underlying brain tumor development or identify new treatments, have had to stop or postpone costly experiments, and are now at risk of losing funding to continue supporting these efforts Here, we sought to address these issues, and evaluate the perceived effects of these changes on neuro-oncology patient care. We asked the international community of healthcare providers, scientists, and trainees in the field to share their experiences during the pandemic. This survey tool is not a method to identify root causes of the problems we identify. This framework will guide further studies and recommendations on how to best take care of CNS cancer patients, support clinical caregivers, and identify opportunities for institutions to continue to advance their research mission. These findings and principles will be broadly applicable to other oncology specialties and those caring for patients with chronic disease.

A c c e p t e d M a n u s c r i p t 8 File 1) was developed by the SNO COVID-19 task force,   composed of adult and pediatric oncologists, surgeons, radiation oncologists, laboratory scientists and patient advocates. The task force generated a set of general questions for all the participants and in addition, we created several pathways based on self-designation [e.g., clinician (neuro-oncologist, neurosurgeon, or radiation-oncologist), scientist, trainee (graduate students, postdocs, residents, and fellows), social worker, training program director].

Participants who were members of more than one group were asked to complete all applicable 

A total of 582 responses were received. Respondents were located in the United States (258, 45%) and internationally (324, 55%) ( Fig. 1) . Of international respondents, Europe (124/582, 21.3%) and Asia (91/582, 15.6%) were the most represented regions, and within these, Spain (37/582, 6.4%) and Japan (19/582 3.3%) were the most common countries of residence ( Fig. 1) . Respondents representing those with direct patient contact included 53.4% physicians (311/582), 2.6% nurse practitioners and physician assistants (15/582), 0.7% nurses (2/582), and 0.2% social workers (1/582); and 7.9% were researchers (46/582) ( Table 1) . Of the clinicians, 71.0% treated adults (341/582), 11.3% children (54/582), and 17.7% treated both (85/582). Within the US, a most clinical practitioners were located at academic centers (79.0% of non-researchers, or 452), compared to private practice (15.2% of non-researchers, or 70).

Regarding beliefs of COVID-19 risk, 50.3% respondents believed that neuro-oncology patients, before any treatment, are at increased risk for contracting the virus (180/487).; 48.9% believed steroids increase susceptibility to SARS-CoV-2 infection (173/487), but 43.8% reported they were unsure and needed more evidence (155/487). Twenty eight percent believed radiotherapy increases infection risk (100/487). Forty six percent believed temozolomide use increases susceptibility (165/487), and 21.6% believed that immunotherapy increases risk (77/487).

The pandemic required changes to clinical practice and clinical trial opportunities, and in (Fig 3) . The effect of COVID19 on non- were delayed by at least two weeks. In cases of modified radiation plans, 68% (17/25) were changed to shorter courses with higher daily doses or shorter courses with a lower total dose (20%, 2/25) (Fig. 4) .

In terms of changes in surgical practice, an average of 60% of elective cases were rescheduled into the future, and remarkably, an average of 37% of elective procedures were canceled. 14.3% (12/84) cases that were planned with an endonasal approach were converted to craniotomy because of guidelines from respective institutions and surgical organizations.

Notably, in cases where there was inadequate personal protective equipment (PPE), approximately 19.5% (16/82) of respondents reported already scheduled surgical procedures proceeding at times or very often.

Neuro-oncology laboratory-based research significantly slowed during the early months 

While approximately 30% (125/433) respondents reported increased work hours since the pandemic started, 37% (160/436) had their salary temporarily reduced. This was higher for respondents who primarily treated adults (38%, 107/ 279) as compared to children (23%, 10/43, p=0.0016). Of those with salary reductions, 53.6% (74/138) had salaries reduced by at least 20% . 4% (16/434) respondents had been furloughed or fired. The majority of respondents in Asia (58.2%, 39/67) reported salary reduction, as compared to 33.2% US respondents (68/205) and 21.6% European respondents (21/97 , p<0.001) (Fig. 5) . Thirty seven percent of clinical practitioners (85/ 228) and 57% of researchers (4/7) reported a severe or moderate to severe fear of loss of job security (p=0.4291). This was higher in private practice (51.1%, 24/47) as compared to academic institutions (37%, 87/238), and was highest in the US (46.4%, 65/140), compared to Europe (34.5%, 20/58) or Asia (37%, 20/55, p= 0.1303). 

There have been several consensus statements and commentaries regarding neurooncology care during the pandemic 6, 7, 14 , and analyses of the caregiver, not-for-profit and brain tumor charity experiences 15,16 . Our international survey provides data that reveal the impact of the pandemic on the practice of neuro-oncology care, its effects on clinical caregivers and patients, and research ( Table 2) A c c e p t e d M a n u s c r i p t 15 difficulty obtaining operating room specimens; or other causes. We also wonder whether this reflects a feeling among providers that what we have to offer patients in terms of treatment does not carry a significant chance of benefit and therefore does not meet a threshold of risk to participate. Comparing these findings to other cancers and diseases will be helpful to identify the root cause of this problem. A study of Canadian oncologists early in the pandemic similarly found that half of respondents reported a cessation of clinical trial accrual 17 . Public pressure by patient advocacy groups, as well as more institutional experience with how to manage clinical trial complexities during crisis, may enable trials to remain open in the future. It was remarkable that clinical practitioners believed that patient satisfaction has increased because of improved communication and travel reduction. This improved satisfaction may also be due to reduced delays in scheduling, which we did not assess. There may be lessons here on how to improve care beyond the pandemic and it will be important to analyze patient and caregiver assessments to corroborate this perception of the care team. For example, respondents deemed virtual platforms beneficial for tumor boards and communication with colleagues and this may represent a lasting positive outcome of this pandemic. In addition, such patient and caregiver-facing studies should evaluate whether the usefulness of technology-assisted visits is evident across the board, or if the elderly or patients in resource-poor settings who find it more difficult to get access to care benefit the most. Lastly, these results provide a platform for future outcomes research aimed at assessing whether subsets of virtual care are inferior, non-inferior, or superior, than traditional health care delivery in terms of medical outcomes, patient/caregiver satisfaction, resource utilization, and financial ramifications to the health care system, families, and society. This may also be occasion to revisit the general usefulness of procedures that were dropped during the pandemic.

Next, the degree of practitioners' worries for their own, and their families' health because of potential exposures they encounter at work is remarkable. It was striking that 15% of surgical procedures proceeded despite inadequate PPE. Dogma is early surgical intervention is A c c e p t e d M a n u s c r i p t 16 beneficial, particularly for patients with aggressive tumors. Many of these procedures were delayed. The impact on survival remains unknown.

A large percentage of respondents faced significant financial loss. Further work is required to determine the long-term effects of these financial changes on productivity and patient outcomes. We also note the significant pressures that exist for clinical practitioners and researchers alike that come from the nature of the pandemic itself. For example, institutions should take measures to support those with children and elder care giving responsibilities.

School closures or schools on altered schedules relying on home education, are likely disproportionately more challenging for women. We did not assess this, but future studies should identify the gender differentials in terms of stress, productivity, and support received. A study of this kind is not without limitations given the fluid nature of the pandemic and varied institutional, national, and international responses. Due to the way that the survey was advertised, it is not possible to calculate a response rate. The number of total responses represent a small proportion of membership in professional organizations that were contacted about participation, suggesting that only a small proportion of the neuro-oncology community was captured by this survey. The survey was offered only in English, which limited participation from non-English speakers. These factors introduce the possibility of selection bias. While we were able to capture the burden providers felt related to the angst over uncertainty and the wellbeing of their patients, staff, families and themselves, we recognize that women and people of diverse backgrounds may have been impacted in ways we did not capture due to the lack of inclusion of these demographic variables. The xenophobia that emerged resulting in bias faced by Asian colleagues and patients reported elsewhere is unprecedented 24 . Our study did not address aspects of discriminatory behavior as a result of the COVID-19 pandemic, nor were we able to assess the impact of stressors faced by women providers and single parents responsible for the care and education of their children.

A c c e p t e d M a n u s c r i p t 18 Our work serves as a baseline appraisal of neuro-oncology during the early months of the pandemic. Evidence suggests practitioners are at risk for burnout. Clinical trial and off-label options are being reduced. Standard treatment options are being modified. New research efforts have been slowed. On the other hand, our assessment provides institutions and advocacy groups with a framework to intervene. As we all learn more, our hope is that such interventions will make oncologic care more efficient and improved on the other side of the pandemic. M a n u s c r i p t 23 

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

Cancer Stat Facts: Brain and Other Nervous System Cancer

Clinical observation of lymphopenia in patients with newly diagnosed glioblastoma

The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells

Caring for patients with cancer in the COVID-19 era

Urgent Considerations for the Neuro-oncologic Treatment of Patients with Gliomas During the COVID-19 Pandemic

Neuro-oncology Management During the COVID-19

Pandemic With a Focus on WHO Grade III and IV Gliomas

Hub and Spoke' Lombardy Neurosurgery G. May we deliver neuro-oncology in difficult times (e.g. COVID-19

The ethics of neuro-oncology in the era of COVID-19: lessons to be learned

Supporting Clinicians During the COVID-19 Pandemic

Medical and Surgical Education Challenges and Innovations in the COVID-19 Era: A Systematic Review

Pandemics and Their Impact on Medical Training: Lessons From Singapore

Letter to the Editor Re: Mohile et al

The brain tumor not-for-profit and charity experience of COVID-19: reacting and adjusting to an unprecedented global pandemic in the 21st century

Brain tumors and COVID-19: the patient and caregiver experience

Impact of COVID-19 on Canadian medical oncologists and cancer care: Canadian Association of Medical Oncologists survey report

Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City

COVID-19 and Cancer: Lessons From a Pooled Meta-Analysis

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan

Racism and discrimination in COVID-19 responses

We want to thank all the participants of the survey for dedicating time to this important effort. 

A c c e p t e d M a n u s c r i p t 20